Fimepinostat has been shown to efficiently reduce MYC protein expression [19], and indeed it was given orphan drug designation for the treatment of relapsed/refractory diffuse B-Cell lymphoma, and has entered phase I clinical testing for pediatric brain tumors with a high incidence of MYC amplification (NCT03893487). The gene discussed is MYC; the disease is brain neoplasm.